MX2016011055A - Nuevo polisacarido y usos del mismo. - Google Patents

Nuevo polisacarido y usos del mismo.

Info

Publication number
MX2016011055A
MX2016011055A MX2016011055A MX2016011055A MX2016011055A MX 2016011055 A MX2016011055 A MX 2016011055A MX 2016011055 A MX2016011055 A MX 2016011055A MX 2016011055 A MX2016011055 A MX 2016011055A MX 2016011055 A MX2016011055 A MX 2016011055A
Authority
MX
Mexico
Prior art keywords
bioconjugates
compositions
host cells
novel polysaccharide
polysaccharide
Prior art date
Application number
MX2016011055A
Other languages
English (en)
Inventor
T Kowarik Michael
L Wetter Michael
J Kemmler Stefan
A Häuptle Micha
Gambillara Veronica
Mally Manuela
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of MX2016011055A publication Critical patent/MX2016011055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0066—Isolation or extraction of proteoglycans from organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a un nuevo polisacárido O de E. coli, O258. También se proporcionan en la presente células hospederas procarióticas que comprende enzimas (por ejemplo, glicosiltransferasas) usadas en la producción de O25B. Las células hospederas proporcionadas en la presente producen bioconjugados de O25B, en donde tales bioconjugados comprenden O25B ligado a una proteína portadora. Además, proporcionadas en la presente están composiciones, por ejemplo, composiciones farmacéuticas, que comprenden O25B y/o bioconjugados que comprenden O258. Tales composiciones pueden ser usadas como vacunas contra la infección con ExPEC, y pueden comprender, además, uno o más bioconjugados adicionales.
MX2016011055A 2014-02-24 2015-02-23 Nuevo polisacarido y usos del mismo. MX2016011055A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943710P 2014-02-24 2014-02-24
PCT/EP2015/053739 WO2015124769A1 (en) 2014-02-24 2015-02-23 Novel polysaccharide and uses thereof

Publications (1)

Publication Number Publication Date
MX2016011055A true MX2016011055A (es) 2017-10-24

Family

ID=52589386

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011055A MX2016011055A (es) 2014-02-24 2015-02-23 Nuevo polisacarido y usos del mismo.

Country Status (19)

Country Link
US (5) US9700612B2 (es)
EP (1) EP3110441B1 (es)
JP (2) JP6276427B2 (es)
KR (1) KR101855142B1 (es)
CN (1) CN106535927B (es)
AR (1) AR100859A1 (es)
AU (1) AU2015220723C1 (es)
BR (1) BR112016019341A2 (es)
CA (1) CA2940547C (es)
CL (1) CL2016002123A1 (es)
EA (1) EA035991B9 (es)
IL (1) IL247344B (es)
LT (1) LT3110441T (es)
MX (1) MX2016011055A (es)
NZ (1) NZ723328A (es)
PH (1) PH12016501671A1 (es)
SG (1) SG11201606889PA (es)
TW (1) TWI639439B (es)
WO (1) WO2015124769A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2718051T3 (es) 2013-01-17 2019-06-27 Arsanis Biosciences Gmbh Antígeno específico de E. coli MDR
CA2940547C (en) 2014-02-24 2021-01-05 Glycovaxyn Ag Novel polysaccharide and uses thereof
US10722580B2 (en) * 2015-05-13 2020-07-28 University Of Washington Compositions and methods for treatment and prevention of uropathogenic E. coli infection
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711637D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
CN108531439B (zh) * 2018-04-16 2020-04-07 南京工业大学 一种大肠杆菌基因工程菌及其构建方法与应用
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
CA3134045A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
CN110018253A (zh) * 2019-04-15 2019-07-16 艾美卫信生物药业（浙江）有限公司 一种生物制品中游离蛋白含量的高效液相测定方法
CN111855826B (zh) * 2019-04-24 2022-09-16 岛津企业管理（中国）有限公司 破伤风类毒素或白喉类毒素的监测方法
GB201908528D0 (en) * 2019-06-13 2019-07-31 Univ Dundee Rhamnose-polysaccharides
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
JP2023530154A (ja) 2020-06-18 2023-07-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート
CA3185642A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
US20230349913A1 (en) * 2020-11-30 2023-11-02 Janssen Pharmaceuticals, Inc. Analytical method for glycogonjugates using a capillary-based immunoassay system
EP4277921A1 (en) 2021-01-12 2023-11-22 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
WO2022178020A1 (en) 2021-02-16 2022-08-25 Duke University Vaccine compositions and methods for the treatment and prevention of urinary tract infections
BR112023019874A2 (pt) 2021-04-01 2023-11-07 Janssen Pharmaceuticals Inc Produção de bioconjugados de e. coli o18
WO2022214620A1 (en) 2021-04-08 2022-10-13 Janssen Pharmaceuticals, Inc. Process for bioconjugate production
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
US20230222313A1 (en) * 2022-01-12 2023-07-13 Dell Products L.P. Polysaccharide archival storage
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
ES2258214T3 (es) 2002-03-07 2006-08-16 Eidgenossische Technische Hochschule Zurich Sistema y procedimiento para la produccion de proteinas glucosiladas recombinantes en un huesped procariotico.
KR101524636B1 (ko) 2005-05-11 2015-06-03 에테하 취리히 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
SI2257307T1 (sl) * 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
PT2501406T (pt) 2009-11-19 2018-02-21 Glaxosmithkline Biologicals Sa Sistema de biossíntese que produz polissacáridos imunogénicos em células procariotas
WO2012078482A1 (en) 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
JP2014526449A (ja) * 2011-09-06 2014-10-06 グリコヴァキシン アーゲー 原核細胞において製造されるバイオコンジュゲートワクチン
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
EP3527663B1 (en) 2012-10-12 2021-12-01 GlaxoSmithKline Biologicals SA Methods of host cell modification
US10287330B2 (en) 2012-12-27 2019-05-14 Glaxosmithkline Biologicals S.A. Methods and compositions relating to CRM197
ES2718051T3 (es) * 2013-01-17 2019-06-27 Arsanis Biosciences Gmbh Antígeno específico de E. coli MDR
EA201690529A1 (ru) 2013-10-11 2016-11-30 Гликоваксин Аг Способы модификации клетки-хозяина
CN106536551B (zh) 2014-02-06 2021-04-16 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
CA2940547C (en) 2014-02-24 2021-01-05 Glycovaxyn Ag Novel polysaccharide and uses thereof
BE1022998B1 (fr) 2014-12-30 2016-10-28 Glycovaxyn Ag Compositions et procédés de glycosylation de protéines
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
CA3134045A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof

Also Published As

Publication number Publication date
US20230364214A1 (en) 2023-11-16
US20200129605A1 (en) 2020-04-30
KR101855142B1 (ko) 2018-05-08
IL247344A0 (en) 2016-11-30
US20150238588A1 (en) 2015-08-27
US11738076B2 (en) 2023-08-29
JP6276427B2 (ja) 2018-02-07
US10940192B2 (en) 2021-03-09
SG11201606889PA (en) 2016-09-29
WO2015124769A1 (en) 2015-08-27
EP3110441B1 (en) 2024-04-03
EA035991B1 (ru) 2020-09-10
KR20160125494A (ko) 2016-10-31
PH12016501671B1 (en) 2016-10-03
CA2940547A1 (en) 2015-08-27
JP6771499B2 (ja) 2020-10-21
AU2015220723A1 (en) 2016-09-22
EA201691478A1 (ru) 2017-02-28
LT3110441T (lt) 2024-04-25
US20210154286A1 (en) 2021-05-27
IL247344B (en) 2020-06-30
EA035991B9 (ru) 2020-10-21
AU2015220723C1 (en) 2018-04-05
NZ723328A (en) 2018-01-26
US20170340718A1 (en) 2017-11-30
TWI639439B (zh) 2018-11-01
US9700612B2 (en) 2017-07-11
CN106535927B (zh) 2019-09-20
TW201615211A (zh) 2016-05-01
PH12016501671A1 (en) 2016-10-03
CL2016002123A1 (es) 2018-02-16
BR112016019341A2 (pt) 2018-01-16
AU2015220723B2 (en) 2017-12-14
US10441647B2 (en) 2019-10-15
JP2018087197A (ja) 2018-06-07
CA2940547C (en) 2021-01-05
AR100859A1 (es) 2016-11-09
EP3110441A1 (en) 2017-01-04
CN106535927A (zh) 2017-03-22
JP2017507178A (ja) 2017-03-16

Similar Documents

Publication Publication Date Title
PH12016501671A1 (en) Novel polysaccharide and uses thereof
MX2022003994A (es) Produccion de oligosacaridos de leche humana en huespedes microbianos con importacion/exportacion dise?ada.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
EP4293104A3 (en) Cell-free production of ribonucleic acid
MX2017005784A (es) Dextranos gelificantes enzimaticamente polimerizados.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
GB2532619A (en) Sirp-Alpha Variant Constructs And Uses Thereof
CN106536569A8 (zh) 可溶性葡聚糖纤维的酶促合成
MX2016008448A (es) Conjugados de var2csa-farmaco.
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
AU2015208482A1 (en) Fusion protein inhibiting angiogenesis or growth and use thereof
AR105464A1 (es) Composiciones probióticas secas estables para usos dietarios especiales
BR112016019735A2 (pt) fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
WO2016168214A3 (en) Immunogenic fusion proteins for the treatment of cancer
MX2021006458A (es) Pared celular de levadura enriquecida en proteina de manano-oligosacarido.
MX2019000137A (es) Cultivos de linea celular de plantas pertinentes al genero de harpagophytum.
MX2017001226A (es) Composicion termogelificante esterilizada.
EP3612199A4 (en) COMMENSAL BACTERIA AS A NEW TREATMENT FOR DRY EYE AND SJÖGREN'S SYNDROME
MX2015012605A (es) Procedimiento para preparar una composición de consomé.
EP4241851A3 (en) Immunogenic compositions
EP4226937A3 (en) Non-neuroinvasive viruses and uses thereof